(Q42686505)

English

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

scientific article published on 23 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections (English)

1 reference

Europe PubMed Central

4 November 2017

1 reference

based on heuristic

inferred from title

author name string

Peggy S McKinnon

1

1 reference

Europe PubMed Central

4 November 2017

Sonja V Sorensen

2

1 reference

Europe PubMed Central

4 November 2017

Larry Z Liu

3

1 reference

Europe PubMed Central

4 November 2017

Kamal Mf Itani

4

1 reference

Europe PubMed Central

4 November 2017

language of work or name

0 references

publication date

23 May 2006

1 reference

Europe PubMed Central

4 November 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

4 November 2017

40

1 reference

Europe PubMed Central

4 November 2017

6

1 reference

Europe PubMed Central

4 November 2017

1017-1023

1 reference

Europe PubMed Central

4 November 2017

Newer treatment options for skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Clinical presentations of soft-tissue infections and surgical site infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

The economic impact of Staphylococcus aureus infection in New York City hospitals

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Efficacy and safety of linezolid in the treatment of skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Prediction Model to Identify Patients WithStaphylococcus aureusBacteremia at Risk for Methicillin Resistance

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1G728

21 January 2018

Identifiers

10.1345/APH.1G728

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42686505&oldid=1965560236"